Comment and reply on: A randomized crossover trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma of chronic obstructive pulmonary disease

被引：3
|
作者：
Macheras, Panos [1 ]
机构：
[1] Univ Athens, Lab Biopharmaceut & Pharmacokinet, Fac Pharm, Athens 15771, Greece
来源：
EXPERT OPINION ON DRUG DELIVERY | 2014年 / 11卷 / 05期
关键词：
D O I：
10.1517/17425247.2014.889648
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：823 / 824
页数：2
相关论文
共 50 条
  • [21] Safety, Tolerability And Pharmacokinetics Of Ciprofloxacin Dry Powder For Inhalation In Patients With Mild To Moderate Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
    Stass, H.
    Nagelschmitz, J.
    Weimann, B.
    Timmer, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [22] Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease A Randomized, Placebo-Controlled, Double-Blind, Crossover Study
    Cazzola, Mario
    Paggiaro, Pierluigi
    Palange, Paolo
    Bjermer, Leif
    Ausin, Pilar
    Carlsson, Lars-Goran
    Ekelund, Jan
    Lotvall, Jan
    CLINICAL DRUG INVESTIGATION, 2012, 32 (03) : 147 - 155
  • [23] INHALATION CHARACTERISTICS WITH SPIROMAX® AND TURBUHALER® DRY POWDER INHALERS (DPI) IN HEALTHY ADULTS AND PATIENTS WITH ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): BEFORE AND AFTER ENHANCED TRAINING
    Chrystyn, H.
    Azouz, W.
    Chetcuti, P.
    Hosker, H.
    Saralaya, D.
    THORAX, 2013, 68 : A178 - A179
  • [24] The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
    Lewis, A.
    Torvinen, S.
    Dekhuijzen, P. N. R.
    Chrystyn, H.
    Watson, A. T.
    Blackney, M.
    Plich, A.
    BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [25] The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
    A. Lewis
    S. Torvinen
    P. N. R. Dekhuijzen
    H. Chrystyn
    A. T. Watson
    M. Blackney
    A. Plich
    BMC Health Services Research, 16
  • [26] Differences in Healthcare Resource Use and Costs Between Post-Discharge Chronic Obstructive Pulmonary Disease Patients Treated with Dry-Powder Inhalers and Pressurized Metered-Dose Inhalers
    Wittbrodt, E. T.
    Millette, L.
    Ferguson, G. T.
    Evans, K.
    Bonafede, M.
    Tkacz, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [27] Inhaler Operability and Patient Satisfaction Regarding Genuair® and Respimat® Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study
    Ohbayashi H.
    Kudo S.
    Ishikawa M.
    Pulmonary Therapy, 2017, 3 (1) : 173 - 185
  • [28] Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough - reply
    Thiadens, HA
    Postma, DS
    BRITISH MEDICAL JOURNAL, 1998, 317 (7165): : 1079 - 1079
  • [29] Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD
    Jogi, Rain
    Mattila, Leena
    Vahteristo, Mikko
    Takala, Aino
    Lahelma, Satu
    Vartiainen, Ville A.
    Lindqvist, Ari
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 1193 - 1201
  • [30] Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease A Randomized Crossover Trial
    Jabbour, Andrew
    Macdonald, Peter S.
    Keogh, Anne M.
    Kotlyar, Eugene
    Mellemkjaer, Soren
    Coleman, Cathie F.
    Elsik, Maros
    Krum, Henry
    Hayward, Christopher S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (17) : 1780 - 1787
12345